The real name and CAS numbe r of the component may be omitted depending on the specific circumstances of the need for confidentiality, but the associated hazards shall be included in the relevant section of the SDS.
Korea
To claim Confidential Business Information (CBI) , companies must submit substitute chemical names and concentration information as well as supporting data to the MoEL for approval.
Harmful chemical substances that may cause serious health hazards to workers, i.e.
- prohibited substances;
- substances requiring permission;
- hazardous substances subject to management;
- harmful factors subject to measurement of the work environment;
- hazardous factors subject to a special health examination
- hazardous chemicals under K-REACH are not eligible for CBI claims.
Upon the MoEL’s review, whether approved or disapproved, companies must provide the information on their MSDS. The information (e.g. approval number and expiration date) of the approval are to be indicated in Section 3 on the MSDS.
*Enforcement date of the standard is January 16th of 2021.
The CBI shall be consistent with the following general principles:
For information otherwise required on labels or SDS, CBI claims shall be limited to the names of chemicals, their identifiers, and their concentrations in mixtures. All other information shall be disclosed on the label and/or SDS, as required;
Where CBI has been withheld, the label or SDS shall so indicate; and
CBI shall be disclosed to the Director-General of Occupational Safety and Health upon request. The confidentiality of the information received is protected under Section 67 of OSHA 1994.
In section 3 information on chemical hazards must be provided.
Generic names may be used in an SDS if the identity of an ingredient is genuinely commercially confidential, and if:
- the ingredient is not any of the following health hazard categories:
| Hazard Class | Hazard Category | Concentration |
|---|
Carcinogenic | Category 1 | ≥ 0.1% |
Germ cell mutagenicity | Category 1 | ≥ 0.1% |
Reproductive toxicity | Category 1 | ≥ 0.1% |
STOT, single exposure | Category 1 | ≥ 1.0% |
STOT, repeated exposure | Category 1 | ≥ 1.0% |
Skin corrosion | Category 1 | ≥ 1.0% |
Serious eye damage | Category 1 | ≥ 1.0% |
Respiratory Sensitization | Category 1 | ≥ 0.1% |
Acute Toxicity | Category 1 to 3 | ≥ 0.1% |
- Or have PEL values as listed in the First Schedule of Workplace Safety and Health (General Provisions) list .
*This information is a summary of SS 586 : Part 3 regulation. Full text is available for charge only
It is possible to use TSN without requesting CBI claim :
It is possible to use TSN without requesting CBI claim :
It is possible to use TSN business has been submitted CBI claim to Taiwan authority:
Acute toxicity categories 4.
Skin corrosion/irritation category 2.
Serious eye damage/irritation category 2A.
Specific target organ toxicity - single exposure category 2.
Specific target organ toxicity - repeated exposure category 2.
Aspiration toxicity cat 1
Withholding Safety Data Sheet content as confidential is prohibited if components are classified as:
Acute toxicity categories 1, 2 or 3.
Skin corrosion/irritation category 1.
Serious eye damage/irritation category 1.
Respiratory or skin sensitizer.
Germ cell mutagenicity.
Carcinogenicity.
Toxic to reproduction.
Specific target organ toxicity - single exposure category 1.
Specific target organ toxicity - repeated exposure category 1.
It is possible to use TSN without requesting a CBI claim . Importers must disclose full composition for DIW (Department of Industrial Works) per B.E. 2558 form, if they import more than 1 000 kilograms per year.
Organizations and individuals producing or importing chemicals have to send a classification and labeling of chemicals and materials related to the Chemicals Agency before 15 (fifteen) working days from the date of the chemical in use and circulation in the market. Information considered as confidential business, organization or individual must notify the Department of Chemical chemicals before putting into use, circulation in the market and to the implementation with other agencies as required.
This page has no comments.